The hereditary type IV collagen disease Alport syndrome leads to kidney failure early in life. Currently there are no specific medications approved for treatment, however, several therapies have been evaluated preclinically and could improve outcome. For that reason, this non-interventional, observational study investigates, if medications (1) delay disease progression; (2) delay time to kidney failure; (3) improve life-expectancy compared to untreated patients (relatives). This observational study started in 2006 as an European registry. Since 2019, this registry has been expanded to "Alport XXL" via the International Alport Alliance as a global effort across all continents. From 2020 on to present, "Alport XXL" has a special focus on the outcomes of early therapy in young patients on ACE-inhibitors vs. Angiotensin-receptor blockers vs. their combination.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
age at onset of end stage kidney failure (need for renal replacement therapy)
Timeframe: until end of observation in 2037
life-expectancy in years (age at death)
Timeframe: until end of observation in 2037
yearly loss of estimated glomerular filtration rate (eGFR)
Timeframe: until end of observation in 2037
time in years until doubling or tripling of urinary albumin to creatinine ratio (UACR)
Timeframe: until end of observation in 2037